CoronaVac SARS-CoV-2 Vaccine Description
According to Sinovac, the CoronaVac SARS-CoV-2 Vaccine candidate is based on an inactivated pathogen.
Sinovac Biotech Ltd. is constructing a commercial vaccine production plant that is expected to manufacture up to 100 million doses of CoronaVac annually.
On May 22, 2020, Sinovac announced a transaction in which Advantech Capital and Vivo Capital have invested $15 million in Sinovac Research and Development Co., Ltd. (“Sinovac R&D”), a wholly-owned subsidiary of Sinovac, to further the development of an inactivated vaccine against COVID-19 named CoronaVac.
CoronaVac SARS-CoV-2 Vaccine Indication
CoronaVac is an experimental vaccine against SARS-CoV-2 which causes the COVID-19 disease.
CoronaVac SARS-CoV-2 Vaccine Dosage
The CoronaVac vaccine is currently packaged as a half-milliliter injection.
CoronaVac SARS-CoV-2 Vaccine News
May 22, 2020 - Sinovac Biotech received approval from governmental authorities to conduct both a phase 1 and phase 2 human clinical trials for CoronaVac in China
May 6, 2020 - Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today the publication of the preclinical study on animals for its vaccine candidate against COVID-19. This is the first challenge study of its SARS-CoV-2 vaccine candidate on animals to prove that the vaccine candidate is safe and provides protection to rhesus macaques.
April 17, 2020 - Sinovac Biotech Ltd. announced that the Company has commenced Phase I clinical trial, a randomized, double-blinded, placebo-controlled study, for its vaccine candidate against COVID-19. Enrollment of the first group of volunteers and the first dose of vaccination for these volunteers have been completed.
April 16, 2020 - Dynavax Technologies Corporation and Sinovac Biotech Ltd. announced a collaboration that will combine Dynavax’s CpG 1018, the adjuvant contained in the U.S. FDA-approved HEPLISAV-B vaccine, with Sinovac’s chemically inactivated coronavirus vaccine candidate.
CoronaVac SARS-CoV-2 Vaccine Clinical Trials
Sinovac received approval from governmental authorities to conduct both Phase I and Phase II human clinical trials in China.
- The Phase I clinical trial, which evaluates the safety, tolerance, and preliminary immunogenicity of CoronaVac, commenced in April 2020.
- The Phase II clinical trial evaluates the immunogenicity and safety of CoronaVac in a larger population in order to define dosage, regimen, and immunization schedule. It is China's first recombinant vaccine candidate for novel coronavirus entering Phase II of a human clinical trial, with 500 volunteer participants. The trial is led by the Jiangsu Provincial Center for Disease Control and Prevention and jointly conducted with the Hubei Provincial Center for Disease Control and Prevention and Zhongnan Hospital of Wuhan University.